Article Details
Retrieved on: 2022-06-05 18:03:57
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Final overall survival (OS) analysis of the phase 3 PALOMA-2 trial (NCT01740427) indicated that palbociclib (Ibrance) in combination with letrozole as ...
Article found on: www.cancernetwork.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here